Study S002236

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07430059
Acronym: SLIM-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 20
Start: 2026-07
Primary completion: 2026-12
Lead sponsor: Vivani Medical, Inc
Conditions: Obesity & Overweight
Interventions: COMBINATION_PRODUCT:Semaglutide Implant (NPM-139); DRUG:Semaglutide (Wegovy) weekly injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Area under the plasma concentration-time curve (AUC) [4 weeks]
Maximum plasma concentration (Cmax) [4 weeks]
Time to maximum semaglutide concentration (Tmax) [4 weeks]
Adverse Events [4 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.